STAGE III PANCREATIC CANCER AJCC V8

This early-phase study tests a combination of two drugs, niraparib and dostarlimab, in 18 adults with BRCA-mutated breast, pancreas, or ovary cancer that has spread or cannot be surgically removed. Niraparib blocks a DNA repair protein in cancer cells, while dostarlimab helps the…

This early-phase study tests whether combining a targeted drug (olaparib), an immunotherapy (durvalumab), and radiation therapy is safe for people with locally advanced pancreatic cancer that cannot be removed by surgery. About 18 participants will receive the combination after i…

This early-stage trial tests a new drug called CA-4948 combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in people with pancreatic cancer that has spread or cannot be removed by surgery. The goal is to find the safest dose and see if the combination can shrink …

This early-phase study tests a new drug (M6620) combined with a standard chemotherapy (irinotecan) in adults with advanced solid tumors that have spread or can't be removed. The main goal is to find the safest dose and check for side effects. About 66 people with cancers like col…

This study tests whether a combination of two drugs, lenvatinib and pembrolizumab, can help keep advanced pancreatic cancer from getting worse. The trial involves 28 adults whose cancer has spread and cannot be surgically removed, and who have already responded to initial treatme…

This study tests a new method called sonoporation, which uses ultrasound and tiny gas bubbles to help chemotherapy drugs get into cancer cells more effectively. The trial includes 120 adults with advanced or hard-to-remove pancreatic cancer who are already receiving standard chem…

This early-stage trial tests two drugs together for people with advanced pancreatic cancer. One drug starves cancer cells by removing a key nutrient, while the other blocks a protein that helps them grow. The goal is to find the safest dose and see if the combination can control …

This early-phase study tests a new drug combination for people with advanced pancreatic cancer that has a specific marker (mesothelin). The treatment pairs a targeted chemotherapy with immunotherapy drugs and standard chemo to see if it's safe and what dose works best. About 74 a…